Above Food Ingredients Stock (NASDAQ: ABVE)

Latest news for Above Food Ingredients (NASDAQ:ABVE) Stock

Above Food Ingredients

Above Food Ingredients Inc specializes in regenerative food ingredients with over 120 product formulations. The company has two main segments: Disruptive Agriculture and Rudimentary Ingredients, and Consumer Packaged Goods ("CPG"). The Disruptive Agriculture and Rudimentary Ingredients segment focuses on regeneratively grown grain and bespoke ingredient products. The CPG segment formulates, manufactures, sells, and distributes consumer product formulations under-owned and private-labeled brands.

Above Food Ingredients Inc. - Common Stock

Above Food Ingredients Inc

Sierra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSRR#NASDAQ">BSRR</a>) reported quarterly earnings of $0.71 per share which beat the analyst consensus estimate of $0.61 by 16.39 percent. This is a 5.97 percent increase over earnings of $0.67 per share from the same period last year.

Earnings

Earnings Beats

News

BSRR

Sierra Q2 EPS $0.71 Beats $0.61 Estimate

Keybanc analyst Jason Celino maintains Coursera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) with a Overweight and lowers the price target from $14 to $12.

Price Target

Analyst Ratings

COUR

Keybanc Maintains Overweight on Coursera, Lowers Price Target to $12

Multi-billion-dollar market cap customer targets scope 1 emissions reduction &nbsp;
Combined with recent orders, this annual recurring revenue at full deployment has the potential to bring company to positive cash flow
WATERTOWN, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Spectaire Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPEC#NASDAQ">SPEC</a>) ("Spectaire"), a pioneer in environmental measurement technology, is pleased to announce initial delivery of AireCore units to its previously announced customer in the energy industry.
"When fully deployed this order, combined with orders received from our Logistics customers, has the potential to generate enough recurring revenue to bring our company to positive cash flow," said Brian Semkiw, CEO of Spectaire.

Contracts

SPEC

Spectaire Announces Delivery Of A 500 AireCore Unit Order With $5M Annual Recurring Revenue Potential To Its Previously Announced Customer In The Energy Industry

General

LOCL

Local Bounti Announces Expanded Distribution With Sam's Club For Its Leafy Greens Production

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) faced a legal setback on Friday when a New Jersey judge rejected its bid to disqualify the law firm Beasley Allen from representing plaintiffs who claim the company&#8217;s talc products caused their cancer.
This decision complicates Johnson &amp; Johnson&#8217;s attempt to resolve over 60,000 claims through a $6.48 billion <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38562078/johnson-johnson-wants-to-deal-with-talc-lawsuit-overhang-proposes-6-5b-settlement-package" rel="noreferrer noopener">pre-packaged bankruptcy plan</a>, Reuters reports.
Judge John Porto of the New Jersey Superior Court ruled that Johnson &amp; Johnson had not provided &#8220;any credible basis&#8221; for its allegations that Beasley Allen partner Andy Birchfield formed an unethical alliance with a former Johnson &amp; Johnson lawyer.
In a related development, U.S. Magistrate Judge Rukhsanah Singh, overseeing talc cases in New Jersey federal court, has ordered Johnson &amp; Johnson to explain why she should not also adopt Porto&#8217;s findings.
Related: <a target="_blank" href="https://www.benzinga.com/news/24/07/39596645/court-rules-against-johnson-johnson-in-talcum-powder-cancer-study-case" rel="noreferrer noopener">Court Rules Against Johnson &amp; Johnson In Talcum Powder Cancer Study Case</a>.
This comes as she considers a similar motion to disqualify Beasley Allen from federal cases. Birchfield expressed his satisfaction with the state court&#8217;s decision, stating that it allows them to continue seeking justice for thousands of women and families affected by Johnson &amp; Johnson&#8217;s talc products.
Citing Erik Haas, Johnson &amp; Johnson&#8217;s worldwide vice president of litigation, Reuters highlighted the company&#8217;s intention to appeal the ruling.
It asserts that it is unethical for plaintiffs&#8217; counsel to collaborate with a former defense counsel on the same issues and claims.
In December, Johnson &amp; Johnson filed motions to disqualify Beasley Allen, accusing Birchfield of unethical conduct by working with James Conlan, a former partner at Faegre Drinker Biddle &amp; Reath who had worked on Johnson &amp; Johnson&#8217;s talc litigation.
Johnson &amp; Johnson claimed Conlan must have disclosed confidential information to Birchfield, but Judge Porto found no evidence to support this.
Johnson &amp; Johnson is currently seeking votes for its bankruptcy plan, which requires the support of 75% of claimants. The voting deadline is next Friday.
Although previous attempts to settle the case in bankruptcy have been rejected, Johnson &amp; Johnson remains confident in its strategy.
Price Action: JNJ stock closed at $154.73&nbsp;on Friday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/06/39419157/johnson-johnson-faces-new-lawsuit-s-related-to-its-talc-products" target="_blank" rel="noreferrer noopener">Johnson &amp; Johnson Faces New Lawsuit(s) Related To Its Talc Products</a>.</li>
</ul>
Photo via Wikimedia Commons

Biotech

Large Cap

Health Care

Legal

Media

Johnson & Johnson Faces Legal Hurdle In Talc Lawsuit Battle

Kandi Technologies Group, Inc. (NASDAQ GS: KNDI) ("Kandi" or the "Company"), a leader in all-electric personal transportation and utility vehicles, today announced that the first batch of its 10K fully electric UTVs, manufactured by its Taiwanese partner Hartford Industrial Co., Ltd. ("Hartford Industrial"), has successfully completed trial production. These vehicles are now packed and ready for delivery to the United States. This marks a significant milestone as Kandi extends its manufacturing operations to Taiwan, aiming to enhance product quality and increase market competitiveness.

Global

KNDI

Kandi Technologies Ships First Taiwan-Made UTV To The U.S.

Stifel analyst Mark Astrachan maintains Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) with a Hold and raises the price target from $157 to $161.

Stifel Maintains Hold on Procter & Gamble, Raises Price Target to $161

<ul>
<li>The extension to a four-year shelf-life helps improve naloxone access as communities continue to grapple with the growing opioid epidemic; product with the extended shelf life has officially begun shipping &nbsp;</li>
</ul>
WINNIPEG, Manitoba, July 22, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions announced the shelf-life extension for NARCAN&#xAE; Nasal Spray from three years (36 months) to four years (48 months) to all newly manufactured product. The update makes NARCAN&#xAE; Nasal Spray the only 4 mg, intranasal naloxone spray in Canada with this extended expiration date. The Health Canada notification to extend NARCAN&#xAE; Nasal Spray's shelf-life was completed on February 2, 2024.

Emergent BioSolutions Announces Shelf-Life Extension For NARCAN Nasal Spray In Canada From 36-Months To 48-Months

Arcutis Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a virtual Key Opinion Leader (KOL) event featuring a leading dermatology and immune-mediated skin disease expert to discuss the unmet need and current treatment landscape for individuals with mild to moderate atopic dermatitis (AD). The event will highlight the differentiating features of and commercialization plans for ZORYVE&#xAE; (roflumilast) cream 0.15%, which recently received FDA approval for the treatment of AD in adults and children down to age 6. &nbsp;
Details for the event are as follows:
Monday, July 29, 2024 8:30am ET To register, <a href="https://www.globenewswire.com/Tracker?data=Br9TCduVg8Mj13dC0XBQU2eNThDGueDHEXET9QJwV9uWSqY4u-kA9nxmafIG9aCK0cKYYOxv68nFAoaqCxZ15S3-Yvl5Z9KIEUaCDvm3BOw=">click here</a>.
Additional information may be accessed at the "<a href="https://www.globenewswire.com/Tracker?data=AO5x2t-aBsH7dp5ixGloYx8Z7kLKYlgT2utUtpAXgB6ChwPiV2fP3sxDPd6EioLlXQVC_j98b_--BodpTyTeAiNq3MiMgpCLTceSUWjUrweYxJ6hb-REMCmFiZaCV8JjrTh7GDPx8858PNm1Jvxlrw==">Events</a>" section of the Company's website.

ARQT

Arcutis To Host ZORYVE Cream 0.15% FDA Approval Call With Key Opinion Leader On Monday, July 29, 2024 at 8:30am ET

Keybanc analyst Sophie Karp maintains CenterPoint Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNP#NYSE">CNP</a>) with a Overweight and lowers the price target from $33 to $31.

Keybanc Maintains Overweight on CenterPoint Energy, Lowers Price Target to $31

HEPA

Pharma Two B To Go Public Through Merger With Hepion Pharmaceuticals; Co. Also Announces $2.9M Private Placement Of Non-Convertible Senior Notes To Institutional Investors

<a href="https://www.globenewswire.com/Tracker?data=xc_ncxbabc92tsHvXycQ05htJldgJGLyJNDWShPr8oqNlMYsmQdL9HsjiFEyDUDYk88jZAknq6Xc__hMIb8vmjQ4uT4B10vFCO-rOAPzLZQ=">Bitcoin Depot Inc.</a> ("Bitcoin Depot" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTM#NASDAQ">BTM</a>), a U.S.-based Bitcoin ATM ("BTM") operator and leading fintech company, today proudly announced that it has achieved and exceeded its ambitious goal of deploying over 8,000 Bitcoin ATMs five months ahead of schedule, with 8,180 kiosks. This milestone reinforces Bitcoin Depot's abiding market dominance and showcases its rapid growth trajectory. The achievement solidifies the Company's <a href="https://www.globenewswire.com/Tracker?data=-0eM1h03kLFI-OKxVypwE8_Zy8AtHS_HPknbMDjdgvSYfhCpq7W1JQYV-GU6WTMTwOnN3p7h9Z3jcT6vfXsk2ezcHHW4gXuQkUXxPtEpojwsaOjbDcfv8BArmwj18_voO7g3_JWuWczuzHyjbUhRU87-xqJo4LSSN3wjSTnIusgoumd3I9m_dz3rWF7jBwq3gavgbTvBTS9oVpmLonQm2A2LdYBJJY_4kNZ3MaaGNUQ=">previously announced</a> achievement of signing 8,000 locations and its year-end objective of having <a href="https://www.globenewswire.com/Tracker?data=zTeKT2E8lCgmvoOKjEMlrU6-5EIqFjc_cxFhhhZIpXz7KnDEBOcpOKxDit8SzZHCYaJ32DRZkqsjKARzUPtJDNd1vsr6ZH94lgmNf83Km29KtbB9exl9WiUHopNVyVi9jw6ZOlolPo6Nm-_kXUaZSbl26hcwIfr5qukjxnDy3pttzptnkPbIaQU-0jtB7VupUqY67-DpypF4iTwLLK0Z4R8yMA0dnci9RLTniZFXtmR-S82o8PGaeiN3z4Z16BARrzq5JTm3s-ga2jmN4vkRbSCOn1Y_t0B77pNCby9SF-8=">the largest installed fleet</a> of BTMs in the Company's history.

Bitcoin Depot Exceeds Goal Of 8,000 Bitcoin ATMs Deployed, 5-Months Ahead Of Schedule

RAPT

Rapt Therapeutics Will Reduce Its Workforce By 47 People, Or Approximately 40% Of Its Existing Headcount, The Company Estimates That It Will Incur Approximately $0.9M In Restructuring Charges-8K

Japan Airlines Orders Up To 20 Additional Boeing 787-9 Jets

ATYR

aTyr Pharma Completes Enrollment Of 268 Patients In Largest Ever Pulmonary Sarcoidosis Study; Topline Data Expected Q3 2025

LILM

Lilium And The Saudi Arabian General Authority of Civil Aviation Sign MoU To Develop And Implement The Required Regulations For eVTOL Operations In Saudi Arabia Beginning In 2026

Study enrolled 268 patients, exceeding target enrollment.
Largest interventional study ever to be conducted in pulmonary sarcoidosis.
Topline data are expected in the third quarter of 2025.
SAN DIEGO, July 22, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATYR#NASDAQ">ATYR</a>), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has completed enrollment in its global pivotal Phase 3 EFZO-FIT&#x2122; study of its lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease with limited treatment options. The study enrolled 268 patients at 85 centers in 9 countries, exceeding target enrollment. Topline data from the study are expected in the third quarter of 2025.

aTyr Pharma Completes Enrollment Of 268 Patients, Exceeding Target Enrollment In Global Pivotal Phase 3 EFZO-FIT Study Of Efzofitimod In Pulmonary Sarcoidosis

MIRA

MIRA Pharmaceuticals Announces New Preclinical Study Results Highlighting Potential Advantages Of Novel Oral Ketamine Analog Ketamir-2 For Neurological And Neuropsychiatric Disorders

<ul>
<li>Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase III trial design to evaluate efti in combination with KEYTRUDA&#xAE; (pembrolizumab), MSD's anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer</li>
<li>TACTI-004 registrational trial will enrol ~750 patients regardless of PD-L1 expression in order to address the entire 1L NSCLC market eligible for anti-PD-1 therapy</li>
</ul>
SYDNEY, AUSTRALIA, July 22, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=IWbOKU012OZzp4o1IuinrbjQp9Q5meXnu_aUpEKhB1ci0qkHUWED1-4WZoOOT2INqzvB8nRLJ0g4nu14WZh9uQ==">Immutep Limited</a> ((ASX: IMM, NASDAQ:<a href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that positive feedback has been received from the US Food and Drug Administration ("FDA") regarding the planned TACTI-004 Phase III trial of eftilagimod alfa ("efti") in combination with KEYTRUDA&#xAE; (pembrolizumab), MSD's anti-PD-1 therapy, and histology-based platinum doublet chemotherapy for the treatment of first-line metastatic non-small cell lung cancer (1L NSCLC), regardless of PD-L1 expression.
The FDA feedback from this Type C meeting, along with feedback previously received from the Paul-Ehrlich-Institut ("PEI") and the Spanish Agency for Medicines and Health Products ("AEMPS"), concludes the preparatory regulatory interactions for the design of this registrational trial. This marks a significant step forward to develop an effective treatment for non-squamous and squamous 1L NSCLC patients who have high, low, or no PD-L1 expression and are eligible for anti-PD-1 therapy.
The TACTI-004 Phase III trial, which will enrol ~750 patients, is based on the positive efficacy and safety data in 1L NSCLC generated from the TACTI-002 Phase II and INSIGHT-003 trials.

IMMP

Immutep Announces Successful Meeting With FDA On Phase III Design In Non-Small Cell Lung Cancer; TACTI-004 Registrational Trial Will Enrol ~750 Patients Regardless Of PD-L1 Expression In Order To Address The Entire 1l NSCLC Market Eligible For anti-PD-1 Therapy

TCBP

TCBP Doses 6th Patient In The ACHIEVE Study In Patients With Acute Myeloid Leukemia

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday morning!



Moving stocks this morning are earnings reports, new agreements, public offerings and more.



We have all of that news ready below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Pineapple Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/pegy-stock-quote/">PEGY</a>) stock is rocketing more than 83% after <a href="https://www.nasdaq.com/press-release/pineapple-energy-formalizes-agreement-conduit-capital-services-and-pursue-working">announcing a new collaboration</a>.</li>



<li>Anew Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/wena-stock-quote/">WENA</a>) shares are soaring over 67% on <a href="https://www.nasdaq.com/press-release/anew-medical-advance-patented-klotho-gene-therapy-neurodegenerative-disorder">therapy advancement plans</a>.</li>



<li>Zapp Electric Vehicles (NASDAQ:<a href="https://investorplace.com/stock-quotes/zapp-stock-quote/">ZAPP</a>) stock is surging more than 47% without any clear news this morning.</li>



<li>60 Degrees (NASDAQ:<a href="https://investorplace.com/stock-quotes/sxtp-stock-quote/">SXTP</a>) shares are gaining over 23% on <a href="https://www.nasdaq.com/press-release/60-degrees-pharma-announces-irb-approval-clinical-study-tafenoquine-treatment">approval of a clinical study</a>.</li>



<li>Trinity Place (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tphs-stock-quote/">TPHS</a>) stock is rising more than 23% with heavy pre-market trading.</li>



<li>Mainz Biomed (NASDAQ:<a href="https://investorplace.com/stock-quotes/mynz-stock-quote/">MYNZ</a>) shares are climbing over 17% after <a href="https://www.nasdaq.com/press-release/mainz-biomed-announces-submission-fda-breakthrough-device-designation-its-next">submitting a test</a> for breakthrough designation.</li>



<li>TC BioPharm (NASDAQ:<a href="https://investorplace.com/stock-quotes/tcbp-stock-quote/">TCBP</a>) stock is jumping more than 17% despite a lack of news.</li>



<li>Interactive Strength (NASDAQ:<a href="https://investorplace.com/stock-quotes/trnr-stock-quote/">TRNR</a>) shares are heading over 13% higher on a <a href="https://www.nasdaq.com/press-release/interactive-strength-inc-nasdaq-trnr-secures-exclusive-distribution-clmbr-fast">distribution agreement and order</a>.</li>



<li>YY Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/yygh-stock-quote/">YYGH</a>) stock is increasing more than 12% without any obvious news.</li>



<li>Srivaru (NASDAQ:<a href="https://investorplace.com/stock-quotes/svmh-stock-quote/">SVMH</a>) shares are up over 12% on <a href="https://www.nasdaq.com/press-release/srivaru-svmh-deploys-advanced-ai-platform-manage-lead-generation-platform-prana-20">artificial intelligence (AI) platform deployment</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Indivior (NASDAQ:<a href="https://investorplace.com/stock-quotes/indv-stock-quote/">INDV</a>) stock is plummeting more than 36% alongside a <a href="https://www.nasdaq.com/press-release/indivior-provides-business-update-conference-call-8-00-am-us-edt-2024-07-09">worrying business update</a>.</li>



<li>Helen Of Troy (NASDAQ:<a href="https://investorplace.com/stock-quotes/hele-stock-quote/">HELE</a>) shares are diving over 23% with the <a href="https://www.nasdaq.com/press-release/helen-troy-limited-reports-first-quarter-fiscal-2025-results-2024-07-09">release of its latest earnings report</a>.</li>



<li>Shapeways (NASDAQ:<a href="https://investorplace.com/stock-quotes/shpw-stock-quote/">SHPW</a>) stock is tumbling more than 19% <a href="https://investorplace.com/2024/07/why-is-shapeways-shpw-stock-up-84-today/">after a rally yesterday</a>.</li>



<li>Novo Integrated Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvos-stock-quote/">NVOS</a>) shares are taking an over 17% beating on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318441400&amp;type=PDF&amp;symbol=NVOS&amp;cdn=2b225bb2253ffcb31b2332a6ef2a7e6d&amp;companyName=Novo+Integrated+Sciences+Inc.&amp;formType=S-1&amp;formDescription=Registration+statement+under+Securities+Act+of+1933&amp;dateFiled=2024-07-08">proposed public offering</a>.</li>



<li>Greenlane (NASDAQ:<a href="https://investorplace.com/stock-quotes/gnln-stock-quote/">GNLN</a>) stock is sliding more than 14% with strong pre-market trading.</li>



<li>Tonix Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/tnxp-stock-quote/">TNXP</a>) shares are decreasing 13% on a <a href="https://finance.yahoo.com/news/tonix-pharmaceuticals-announces-proposed-public-210000234.html">proposed public offering</a>.</li>



<li>Above Food Ingredients (NASDAQ:<a href="https://investorplace.com/stock-quotes/abve-stock-quote/">ABVE</a>) stock is falling over 11% without any apparent news.</li>



<li>Qualigen Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/qlgn-stock-quote/">QLGN</a>) shares are retreating 11% on Tuesday morning.</li>



<li>Helios Technologies (NYSE:<a href="https://investorplace.com/stock-quotes/hlio-stock-quote/">HLIO</a>) stock is slipping more than 10% on <a href="https://www.nasdaq.com/press-release/helios-technologies-announces-leadership-team-update-2024-07-08">changes to its leadership team</a>.</li>



<li>Inuvo (NYSEMKT:<a href="https://investorplace.com/stock-quotes/inuv-stock-quote/">INUV</a>) shares close out our pre-market stock movers down over 10%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-july-9th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth keeping an eye on and we have a breakdown of all the biggest ones to watch on Friday!



Moving stocks are mergers, clinical trial data, public offerings and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Crown LNG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBS#NASDAQ">CGBS</a>) stock is rocketing almost 154% after <a href="https://finance.yahoo.com/news/crown-lng-holding-announces-completion-201700767.html">recently completing a business combination</a>.</li>



<li>Toyo (NASDAQ:<a href="https://investorplace.com/stock-quotes/toyo-stock-quote/">TOYO</a>) shares are soaring close to 111% alongside heavy pre-market trading.</li>



<li>Sentage (NASDAQ:<a href="https://investorplace.com/stock-quotes/sntg-stock-quote/">SNTG</a>) stock is surging over 60% with strong early morning trading.</li>



<li>Above Food Ingredients (NASDAQ:<a href="https://investorplace.com/stock-quotes/abve-stock-quote/">ABVE</a>) shares are increasing more than 42% without any clear news this morning.</li>



<li>Monterey Capital Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/mcac-stock-quote/">MCAC</a>) stock is gaining over 23% on Friday morning.</li>



<li>Maxeon Solar Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/maxn-stock-quote/">MAXN</a>) shares are rising more than 19% with heavy early morning trading.</li>



<li>Qualigen Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/qlgn-stock-quote/">QLGN</a>) stock is heading nearly 16% higher with strong pre-market trading.</li>



<li>Immutep (NASDAQ:<a href="https://investorplace.com/stock-quotes/immp-stock-quote/">IMMP</a>) shares are climbing over 15% with <a href="https://www.nasdaq.com/market-activity/stocks/immp/press-releases">positive clinical results</a>.</li>



<li>Big Tree Cloud (NASDAQ:<a href="https://investorplace.com/stock-quotes/dsy-stock-quote/">DSY</a>) stock is jumping more than 14% on Friday.</li>



<li>Instil Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/til-stock-quote/">TIL</a>) shares are up over 14% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Shineco (NASDAQ:<a href="https://investorplace.com/stock-quotes/sisi-stock-quote/">SISI</a>) stock is crashing more than 44% on a <a href="https://www.nasdaq.com/press-release/shineco-announces-proposed-underwritten-public-offering-2024-07-11">proposed public offering</a>.</li>



<li>ASP Isotopes (NASDAQ:<a href="https://investorplace.com/stock-quotes/aspi-stock-quote/">ASPI</a>) shares are diving over 19% as it also announces a <a href="https://www.globenewswire.com/news-release/2024/07/11/2912107/0/en/ASP-Isotopes-Announces-Proposed-Public-Offering-of-Common-Stock.html">proposed public offering</a>.</li>



<li>Cyngn (NASDAQ:<a href="https://investorplace.com/stock-quotes/cyn-stock-quote/">CYN</a>) stock is tumbling 18% following a <a href="https://www.nasdaq.com/press-release/more-1bn-annual-sales-alta-equipment-group-joins-cyngns-dealer-network-2024-07-11">massive rally yesterday</a>.</li>



<li>Kazia Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) shares are retreating more than 16% <a href="https://investorplace.com/2024/07/kzia-stock-alert-kazia-continues-its-surge-on-thursday-with-51-gains/">after rallying this week</a>.</li>



<li>Nano Nuclear Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/nne-stock-quote/">NNE</a>) stock is taking an over 12% beating after <a href="https://www.nasdaq.com/press-release/nano-nuclear-energy-announces-pricing-upsized-18-million-underwritten-offering-2024">pricing an upsized underwritten offering</a>.</li>



<li>Biodexa Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/bdrx-stock-quote/">BDRX</a>) shares are falling more than 10% after jumping yesterday on <a href="https://seekingalpha.com/news/4123698-biodexa-stock-rallies-amid-release-of-phase-2-data-for-erapa">clinical trial data</a>.</li>



<li>Digital Brands Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/dbgi-stock-quote/">DBGI</a>) stock is dropping over 10% this morning.</li>



<li>Sonoma Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/snoa-stock-quote/">SNOA</a>) shares are decreasing more than 10% following a Thursday rally.</li>



<li>Forward Industries (NASDAQ:<a href="https://investorplace.com/stock-quotes/ford-stock-quote/">FORD</a>) stock is dipping 10% without any news to report.</li>



<li>Nuwellis (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuwe-stock-quote/">NUWE</a>) shares close out our pre-market stock movers down over 9% this morning.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-july-12th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Above Food Ingredients (ABVE) has released an update. Above Food Ingredients Inc. is poised to revolutionize sustainable agriculture with innovativ...

Above Food Ingredients: Pioneering Sustainable Agriculture

ABVE

ASPI

BDRX

CGBS

DBGI

FORD

GNLN

HELE

HLIO

INDV

INUV

KZIA

MAXN

MCAC

MYNZ

NUWE

NVOS

PEGY

QLGN

SHPW

SISI

SNOA

SNTG

SVMH

SXTP

TNXP

TOYO

TPHS

TRNR

WENA

YYGH

ZAPP

Press Releases

Above Food Begins Trading Today on Nasdaq Under Symbol "ABVE"

Above Food Sets Business Update Conference Call for July 25, 2024

BITE

Above Food Corp. ("Above Food"), an innovative food company leveraging its vertically integrated supply chain to deliver differentiated ingredients and consumer products, today announced that the common shares and warrants of Bite Acquisition Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BITE#NYSE">BITE</a>) and Above Food respectively, are expected to begin trading today, July 1, under the combined company, Above Food Ingredients Inc., on the Nasdaq Stock Market ("Nasdaq") under the ticker symbols "ABVE" and "ABVE.W", respectively.

Above Food Begins Trading Today On Nasdaq Under Symbol "ABVE"

Above Food common shares and warrants expected to begin trading on Nasdaq on July 1, 2024 under ticker symbols "ABVE" and "ABVE.W", respectively &nbsp;Above Food is a scaled food company leveraging its vertically integrated supply chain to deliver differentiated ingredients to ~260 customers globally and consumer products to ~35,000 retail points of distributionCALGARY, Alberta and NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Above Food Corp. ("Above Food" or the "Company"), an innovative food company leveraging its vertically integrated supply chain to deliver differentiated ingredients and consumer products, and Bite Acquisition Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BITE#NYSE">BITE</a>) ("Bite"), a special purpose acquisition company, today announced the completion of their previously announced business combination (the "Business Combination"). The Business Combination was approved at a special meeting of Above Food shareholders on June 7, 2024 and a special meeting of Bite's stockholders on April 29, 2024, and it closed on June 28, 2024.

Above Food And Bite Acquisition Announce Completion Of Business Combination, To Begin Trading On Nasdaq On July 1, 2024 Under Ticker Symbol "ABVE"

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Above Food Ingredients

News

Latest news for Above Food Ingredients (NASDAQ:ABVE) Stock

Monday, July 01, 2024

Friday, June 28, 2024